1. Home
  2. RDI vs SKYE Comparison

RDI vs SKYE Comparison

Compare RDI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.10

Market Cap

24.8M

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.71

Market Cap

23.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
SKYE
Founded
1937
2012
Country
United States
United States
Employees
2025
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
23.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RDI
SKYE
Price
$1.10
$0.71
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
22.6K
331.8K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.57
52 Week High
$1.65
$5.75

Technical Indicators

Market Signals
Indicator
RDI
SKYE
Relative Strength Index (RSI) 43.73 52.16
Support Level $0.98 $0.68
Resistance Level $1.16 $0.83
Average True Range (ATR) 0.07 0.04
MACD -0.01 0.01
Stochastic Oscillator 15.97 84.95

Price Performance

Historical Comparison
RDI
SKYE

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: